Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.

ABSTRACT: Trastuzumab is commonly used in the treatment of human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, but its efficacy is often limited by the emergence of chemoresistance. Recent studies indicate that exosomes act as vehicles for exchange of genetic cargo between heterogeneous populations of tumor cells, engendering a transmitted drug resistance for cancer development and progression. However, the specific contribution of breast cancer-derived exosomes is poorly understood. In this study, publicly available expression profiling data from breast cancer and bioinformatics analyses were used to screen potential miRNAs in trastuzumab resistance. A series of gain- or loss-functional assays were performed to define the function of miR-567 and ATG5 in trastuzumab resistance

SUBMITTER: Han M 

PROVIDER: S-EPMC6976584 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature